GSA Capital Partners’s SpringWorks Therapeutics SWTX Stock Holding History

GSA Capital Partners’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,560	Closed	-$378K	–	2134
2025 Q1	$378K	Sell	8,560 -6,077	-42%	-$280K	0.03%	992
2024 Q4	$529K	Buy	14,637 +8,125	+125%	+$284K	0.04%	847
2024 Q3	$209K	Buy	+6,512	New	+$243K	0.02%	1404

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

GSA Capital Partners's SWTX Position: Q2 2025 in Review

GSA Capital Partners sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 8,560 shares — an estimated $378K sold.

GSA Capital Partners first reported a position in SWTX in Q3 2024 and held it in 3 quarters. The position peaked at $529K in Q4 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

GSA Capital Partners reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 8,560 SpringWorks Therapeutics shares in Q2 2025, an estimated $378K.
GSA Capital Partners first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 3 quarters.
GSA Capital Partners's SpringWorks Therapeutics position peaked at $529K in Q4 2024.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.